improv outlook
volum set lab beat consensu estim
rais forecast price target
laboratori corp america
introduc new code antibodi test
reimburs rate code inform click
new rate effect retroact repres meaning
step prior reimburs see exhibit addit covid-
molecular test continu expand includ asymptomat
popul beyond four wall hospit exhibit three
phase test quest labcorp benefit proport quest
account molecular test base
rais forecast consensu
lh respect updat estim reflect higher serolog
reimburs rate higher molecular test volum molecular
serolog test expect account test mix remaind
think higher reimburs translat meaning expans
 y/i averag realiz price per requisit updat
estim accordingli
quest model ep versu
consensu made materi chang ep
estim see room forecast come time
test continu next year labcorp model ep
versu consensu ep
quest rais price target use sum
part valuat framework account relat profit stream
next month assign multipl estim compani core
earn power repres quest year averag discount
 in-line prior valuat methodolog assign
multipl estim compani covid earn power
higher multipl combin compani core multipl
increment multipl point in-line averag pe multipl
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
expans sinc market trough rel
compani benefit covid test includ abbott becton
dickinson thermo fischer
labcorp rais price target use sum
part valuat framework account relat profit stream
next month assign multipl estim compani core
earn power repres labcorp year averag discount
 in-line prior valuat methodolog assign
multipl estim compani covid earn power
higher multipl combin compani core multipl
increment multipl point in-line averag pe multipl
expans sinc market trough rel
compani benefit covid test
exhibit phase serolog test
exhibit three phase dianost
risk reward laboratori corp america hold lh
lt share gain opp pref payor partnership cro faster growth
multipl appli core earn power
multipl appli core earn power multipl deriv current
multipl minu lh year averag discount
multipl appli covid earn power
multipl appli covid earn power multipl base
compani core multipl plu averag pe multipl expans sinc
market trough rel pseen covid test compani
includ
labcorp second largest refer
lab compani matur industri
plan open lab
contract establish long-term strateg
partnership labcorp quest
diagnost set stage ration
price share gain opportun
posit lab rel safe haven
within hc servic sector
headwind
reimburs pressur exposur
quanti factor ms/market
cro diversi labcorp busi
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
pt base sum part
multipl appli bull case ep
multipl appli bull case ep
multipl deriv current multipl
plu lh year peak discount
pt base sum part
multipl appli core earn
multipl appli core earn
power
power multipl deriv
current multipl minu lh
year averag discount
pt base sum part
multipl appli bear case ep
multipl appli bear case ep
multipl deriv current multipl
minu lh year trough discount
multipl appli covid earn
multipl appli covid earn
power
power multipl base
compani core multipl plu
sinc market trough rel
 pseen covid test
multipl appli covid earn
multipl appli covid earn
power
power multipl base
compani core multipl plu
sinc market trough rel
 pseen covid test
multipl appli covid earn
multipl appli covid earn
power
power multipl base
compani core multipl plu
sinc market trough rel
 pseen covid test
 risk reward laboratori corp america hold lh
laboratori corpor america hold
laboratori corpor america hold
volum growth less scale region
player prefer lab network
china india
view explan region hierarchi
research highest favor quintil
higher core volum growth faster
expect share gain region
revers pama cut
medicar reimburs pressur
abat revers
covanc chiltern deal synergi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
nt slowdown core test potenti off-set test
base case multipl
base case multipl deriv multipl repres current minu
year discount appli core earn power multipl
appli covid earn power base core multipl plu averag
pe multipl expans sinc market trough rel pseen
largest nation
lab market share physician lab
unit decis establish long-term
strateg partnership two nation
lab labcorp set
stage ration price provid
quest opportun gain market share
next three year
capit deploy form tuck-in
strategi cost cut program
invigor increas test mix toward
advanc molecular diagnost
near term slowdown physician ofc
visit meaning headwind
core test xed cost busi
view descript risk reward theme
multipl bull case ep
bear case multipl
bear case multipl deriv
minu year peak premium
 appli core earn power
multipl appli covid earn
power base core multipl plu
sinc market trough rel
 pseen covid test
base case ep
base case multipl
base case multipl deriv
minu year discount
appli core earn power
multipl appli covid earn power
base core multipl plu
market trough rel
 pseen covid test
multipl bear case ep
bear case multipl
bear case multipl deriv
minu year trough discount
 appli core earn power
multipl appli covid earn
power base core multipl plu
sinc market trough rel
 pseen covid test
volum growth move in-network
bcbsnj less scale region
player well prefer lab
view explan region hierarchi
research highest favor quintil
higher core volum growth faster
expect share gain region
revers pama cut
consolid driver higher benet
volum growth share gain meet
save program magnitud come
expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
